Kedrion S.p.A.

Industry · 9 registered clinical trials — 3 currently recruiting.

Status	Trial	Phase	Started
Recruiting	A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammator Chronic Inflammatory Demyelinating Polyneuropathy	Phase 3	2026-04-01
Recruiting	A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis Acquired Factor X Deficiency	Phase 3	2026-02-01
Recruiting	A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopen Chronic Primary Immune Thrombocytopenia (ITP)	Phase 3	2025-08-13
Active Not Recruiting	Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES1 Primary Immunodeficiency Disease	Phase 3	2021-03-31
Completed	Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients Primary Immunodeficiency Disease	Phase 3	2019-04-30
Terminated	Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric P Hypovolemia	Phase 4	2015-02-05
Completed	Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients Ligneous Conjunctivitis	Phase 2 / Phase 3	2013-05-22
Completed	Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia	Phase 3	2012-11-12
Available	Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population Ligneous Conjunctivitis	—	—